Studies investigating the role of SOD2 in radiation protection following irradiation cancer therapy in human neuroblastoma, Ewing sarcoma, breast cancer, bladder cancer, colon cancer, prostate cancer, and lung cancer cells demonstrated that low-dose irradiation (2–100 cGY) increased NFκB activation and consequently increased SOD2 expression, as well as the survival/clonal expansion of cells (11). Here, SOD2 is linked to prostate carcinoma.